Pure Tinnitus Group Coaching: A Telehealth Innovation Inspired by COVID-19
BERKELEY, CALIFORNIA – California-based telehealth startup Pure Tinnitus has developed Pure Tinnitus Group Coaching as a way to provide evidence-based tinnitus management techniques via Zoom video. The Covid-19 pandemic has made living with tinnitus more challenging. The pandemic has led to increased social isolation, staying at home, and stress around healthcare. All of these factors negatively impact…
Read MoreFuture of Hearing Healthcare Conference Schedule Announced
Hearing Health & Technology Matters (HHTM), a leading online resource for hearing professionals and consumers with hearing loss, is pleased to announce the release of the detailed schedule of events for the first ever Future of Hearing Healthcare Conference. The two day virtual event will take place on March 17th and 18th, with a focus…
Read MoreHearX Group Raises $8.3M, Led by Bose Ventures, to Enhance Hearing Care Strategy
PRETORIA, SOUTH AFRICA — hearX Group, an impact-driven scale-up with a mission to increase access to hearing healthcare through smart digital solutions, has completed a multimillion-dollar funding round led by Bose Ventures, the United States venture capital group within Bose Corporation. Bose Ventures invested $3m in the round. HAVAÍC, which invests in and supports early-stage, high-growth African…
Read MoreNew Study Establishes First Benchmarks for Prevalence and Risk factors for Cisplatin-Induced Hearing Loss in Children
LOS ANGELES, CALIFORNIA — Cisplatin is one of the most effective chemotherapy agents, used in just under half of pediatric cancer cases. Permanent hearing loss is a common side effect of this medication, but until now, studies have been too small and too varied to accurately characterize this risk. Last week in The Lancet Child…
Read MoreDecibel Therapeutics Announces Pricing of Initial Public Offering; Raises $127M
BOSTON, MASSACHUSSETTS — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced the pricing of its initial public offering (IPO) of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares…
Read MorePipeline Therapeutics Raises $80 Million Series C Financing
SAN DIEGO, CALIFORNIA – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, announced the closing of an $80 million Series C financing. The oversubscribed financing was led by a healthcare-focused new investor, with participation by other new investors including Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara…
Read MoreStarkey’s Bill Austin Celebrates 60 Years in the Hearing Industry
EDEN PRAIRIE, MINNESOTA – Today, Starkey is celebrating its inaugural Founder’s Day, as owner and Chairman Bill Austin marks 60 years of helping people with hearing health care around the globe. Minnesota Governor Tim Walz has also proclaimed February 10, 2021, as William F. Austin and Starkey Day in the state of Minnesota. It was on this…
Read MoreFrequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
WOBURN, MASSACHUSSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will…
Read MoreStudy Finds Self-Reported Hearing Loss Linked to Increased Risk of Dementia
SYDNEY, AUSTRALIA — A six-year study of older Australians in the Centre for Healthy Brain Ageing (CHeBA) Sydney Memory and Ageing Study has uncovered an association between the impact of hearing loss on cognitive abilities and increased risk for dementia. In Australia, hearing loss affects 74% of people aged over 70. International studies estimate that…
Read MoreDecibel Therapeutics and Catalent Partner to Develop Gene Therapy for Treatment of Congenital Hearing Loss
SOMERSET, NEW JERSEY & BOSTON, MASSACHUSSETTS — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, today announced they have signed…
Read More